Epalrestat is an aldose reductase inhibitor (ARI) used primarily to treat diabetic peripheral neuropathy. It works by inhibiting the enzyme aldose reductase, which is responsible for converting glucose to sorbitol in the polyol pathway. Excessive sorbitol accumulation contributes to diabetic complications, and epalrestat helps prevent nerve damage by reducing this pathway’s activity.
Epalrestat is administered orally and is one of the few ARIs approved for clinical use, particularly in Japan, India, and select Asian countries.
Indications include:
∙ Diabetic peripheral neuropathy
∙ Investigational use in other diabetic microvascular complications (e.g., retinopathy, nephropathy)
Epalrestat is synthesized via multi-step organic synthesis involving thioacrylic acid derivatives and heterocyclic intermediates. Impurities may arise from synthetic steps or degradation. Given its chronic oral administration, impurity levels must meet ICH Q3A/B standards.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Epalrestat is used to treat diabetic peripheral neuropathy by reducing excess sorbitol formation in nerve cells, which helps improve symptoms like numbness, tingling, and pain.
It inhibits aldose reductase, the enzyme that converts glucose to sorbitol, thereby preventing sorbitol-induced cellular damage in nerves.
Store at room temperature, protected from light and moisture. Keep in a tightly closed container to prevent degradation.
Yes, it is generally well-tolerated for chronic use in diabetic patients, but liver function monitoring is advised during therapy.
